Reshaping Nucleic Acids, Reversing Disease

Gene abnormalities often result in the manufacture of too little or too much protein, causing a myriad of life-threatening diseases, such as cancer. 

Reglagene's medicines target the protein production problem at the source—the gene—and gets it back to functioning properly.

Reglagene develops Epigenetic Medicines that regulate cancer genes

quad genes reglagene_3x.png

Too often cancer survivors hear the life-shattering words, Your cancer is back.” Cancer changes itself to nullify even the most effective treatments. Therapy resistance is the greatest challenge cancer patients face today. At Reglagene, we develop Epigenetic Medicines that attack the root causes of therapy resistance to keep cancer patients responsive to treatment. 

When cancer is confronted with therapy, it responds with genetic modifications that alter its gene expression to become resistant. What patients need is a way to effectively reverse cancer's genetic changes that enable treatments to work better and longer. That's where Reglagene's Epigenetic Medicines become crucial in helping cancer patients overcome therapy resistance. Reglagene's Epigenetic Medicines target the gene itself and get it back to functioning properly. 

Reglagene is on a mission to discover and develop low-cost and noninvasive therapeutic solutions that reprogram genes exploited by cancer. 



Unlike gene-editing technologies, Reglagene’s approach results in therapeutic effects that last only as long as the medicine is on board. This means that once the treatment is ended and the cancer has been eliminated, the body will return to its natural, healthy state. This approach also provides an added measure of safety. If adverse effects are observed in the patient, treatment can be stopped.


Reglagene’s technology is not a binary on or off switch for gene expression. Depending on the amount of medicine on board and the desired effect, gene expression can be dialed up or down based on the therapeutic need.



Reglagene’s technology for creating new medicines leverages unique DNA structural features to identify medicines that act on specific genes to create targeted therapies based on the genetic makeup of a patient’s tumor.


We access the advantages of what are known as small-molecule medicines: variable routes of administration (including oral and intravenous), lowest manufacturing costs relative to other therapeutic modalities, and well-traveled development and regulatory pathways.



1703 E Mabel St  |  Tucson,  AZ  85721  |   USA

Success! Message received.